1337P Real-world utilization and outcomes of dacomitinib as first-line therapy in Asian patients with advanced EGFR mutation–positive NSCLC: An interim analysis of the ARIA study.

Authors :: Wu, L.
Li, J.
Xu, C.
Biswas, B.
Tang, K.
Wang, H.
Liu, Z.
Batra, U.
Ho, G.F.
Low, S.H.J.
Lu, Y.
Zhao, M.
Tho, L.M.
Zhao, J.
He, S.
Huang, J.
Tang, X.
Wong, C.H.
Wu, Y-L.
Source :: Annals of Oncology. 2023 Supplement 2, Vol. 34, pS771-S771. 1p.
Publication Year :: 2023

Subjects :: *ASIANS
*EPIDERMAL growth factor receptors
*ARIA
*NON-small-cell lung carcinoma

Full Text Access

Tools